Kymera Therapeutics, Inc. Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc.

KYMR

Κατάταξη σε μετοχές #2158
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to... Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Τιμή μετοχής
$112.26
Κεφαλαιοποίηση
$9.23B
Αλλαγή (1 ημέρα)
-0.33%
Αλλαγή (1 έτος)
101.18%
Χώρα
US
Εμπόριο Kymera Therapeutics, Inc. (KYMR)

Κατηγορία

Healthcare
Ιστορικό τιμής μετοχής για την Kymera Therapeutics, Inc. (KYMR)
Υψηλότερη τιμή κλεισίματος: $109.27 στις 2026-10-01

Χαμηλότερη τιμή κλεισίματος: $31.67 στις 2020-08-01
Ιστορικό τιμής μετοχής της Kymera Therapeutics, Inc. από 2020 έως 2026
Ετήσια απόδοση τιμής μετοχής
Έτος Απόδοση
2026 (TTM) 12.16%
2025 87.59%
2024 77.01%
2023 -11.39%
2022 -52.05%
2021 -12.80%
2020 0.00%
Τιμή μετοχής για παρόμοιες εταιρείες ή ανταγωνιστές
Εταιρεία Τιμή μετοχής Μεταβολή 1Έτ% Χώρα
$536.13 25.72%
US
$200.12 645.31%
US
$137.83 -3.78%
AU
$291.76 2.51%
BE
$880.01 8.09%
NL